Barclays PLC Has $236,000 Holdings in Zynex, Inc. (NASDAQ:ZYXI)

Barclays PLC lifted its stake in Zynex, Inc. (NASDAQ:ZYXI) by 43.3% in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 28,821 shares of the company’s stock after purchasing an additional 8,713 shares during the quarter. Barclays PLC owned 0.09% of Zynex worth $236,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors have also made changes to their positions in ZYXI. Renaissance Technologies LLC lifted its position in Zynex by 68.7% in the 2nd quarter. Renaissance Technologies LLC now owns 189,762 shares of the company’s stock worth $1,769,000 after buying an additional 77,300 shares in the last quarter. Millennium Management LLC grew its stake in Zynex by 66.5% in the second quarter. Millennium Management LLC now owns 297,082 shares of the company’s stock valued at $2,769,000 after purchasing an additional 118,615 shares in the last quarter. Jane Street Group LLC increased its position in Zynex by 8.9% in the 3rd quarter. Jane Street Group LLC now owns 23,530 shares of the company’s stock worth $192,000 after purchasing an additional 1,929 shares during the last quarter. Quest Partners LLC raised its stake in shares of Zynex by 131.3% during the 3rd quarter. Quest Partners LLC now owns 29,898 shares of the company’s stock worth $244,000 after purchasing an additional 16,972 shares in the last quarter. Finally, American Century Companies Inc. lifted its holdings in shares of Zynex by 10.1% during the 2nd quarter. American Century Companies Inc. now owns 31,159 shares of the company’s stock valued at $290,000 after buying an additional 2,864 shares during the last quarter. 29.68% of the stock is currently owned by institutional investors and hedge funds.

Insiders Place Their Bets

In related news, CFO Daniel J. Moorhead sold 10,000 shares of the business’s stock in a transaction dated Friday, November 1st. The stock was sold at an average price of $8.59, for a total transaction of $85,900.00. Following the completion of the transaction, the chief financial officer now owns 44,878 shares of the company’s stock, valued at approximately $385,502.02. The trade was a 18.22 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders sold a total of 44,000 shares of company stock valued at $368,040 in the last quarter. Insiders own 52.13% of the company’s stock.

Wall Street Analyst Weigh In

Several equities analysts recently weighed in on the stock. Royal Bank of Canada cut their price objective on shares of Zynex from $12.00 to $11.00 and set an “outperform” rating on the stock in a research report on Tuesday, October 8th. HC Wainwright reaffirmed a “buy” rating and issued a $17.00 price objective on shares of Zynex in a research note on Friday, December 6th.

Zynex Stock Down 2.4 %

Shares of ZYXI stock opened at $7.68 on Tuesday. The stock’s 50 day simple moving average is $8.13 and its 200 day simple moving average is $8.28. Zynex, Inc. has a twelve month low of $7.15 and a twelve month high of $13.77. The company has a debt-to-equity ratio of 1.66, a quick ratio of 3.15 and a current ratio of 3.94. The company has a market capitalization of $244.61 million, a price-to-earnings ratio of 51.20 and a beta of 0.53.

Zynex (NASDAQ:ZYXI) last released its quarterly earnings results on Thursday, October 24th. The company reported $0.07 EPS for the quarter, beating analysts’ consensus estimates of $0.06 by $0.01. The company had revenue of $49.97 million for the quarter, compared to analyst estimates of $50.83 million. Zynex had a net margin of 2.49% and a return on equity of 13.05%. The company’s quarterly revenue was up .1% compared to the same quarter last year. During the same quarter last year, the firm posted $0.10 earnings per share. As a group, research analysts predict that Zynex, Inc. will post 0.2 EPS for the current year.

Zynex Profile

Zynex, Inc, together with its subsidiaries, designs, manufactures, and markets medical devices to treat chronic and acute pain; and activate and exercise muscles for rehabilitative purposes with electrical stimulation. The company offers NexWave, a dual channel, multi-modality interferential current, transcutaneous electrical nerve stimulation, and neuromuscular electrical stimulation (NMES) device that is marketed to physicians and therapists by field sales representatives; NeuroMove, an electromyography and electric stimulation technology device; InWave, an electrical stimulation product for the treatment of female urinary incontinence; E-Wave, an NMES device; M-Wave, an NMES device.